Rainer J Klement1, Detlef Meyer2, Stefan Kanzler2, Reinhart A Sweeney3,2. 1. Department of Radiation Oncology, Leopoldina Hospital Schweinfurt, Robert-Koch-Straße 10, 97422, Schweinfurt, Germany. rainer_klement@gmx.de. 2. Darmzentrum Leopoldina Hospital, Schweinfurt, Germany. 3. Department of Radiation Oncology, Leopoldina Hospital Schweinfurt, Robert-Koch-Straße 10, 97422, Schweinfurt, Germany.
Abstract
PURPOSE: Interest in ketogenic diets (KDs) as complementary nutritional treatments for cancer patients is rising, although some skepticism about their safety exists. We, therefore, studied the effects of KDs on quality of life and blood parameters in rectal cancer patients undergoing radio-chemotherapy. METHODS: EORTC-QLQ30 questionnaire scores and different metabolic and hormonal blood parameters were obtained prior to, in the middle of and at the end of radiotherapy within the KETOCOMP study (ClinicalTrials.gov Identifier: NCT02516501). A total of 18 patients consuming a KD were compared to 23 patients consuming their standard diet (SD). Baseline-end differences were measured using Wilcoxon tests, and repeated measures analysis was performed using linear mixed effects models. RESULTS: Eighty-nine percent of patients on the KD reported subjectively feeling good or very good, but roughly half of them rated the daily routine implementation as difficult. Only the SD group experienced significant declines in physical and role functioning, while the KD group improved in role (p = 0.045), emotional (p = 0.018) and social functioning (p = 0.009).Urinary frequency, buttock pain and fatigue significantly increased in the SD group, but to a much lesser extent in the KD group. Several biomarkers of metabolic health (gamma-glutamyl-transpeptidase, triglyceride-glucose index, HDL cholesterol/triglyceride ratio, and free T3) improved in the KD, but not the SD group. CONCLUSIONS: Despite being perceived as difficult to implement by ≈50% of patients, KDs are feasible as complementary therapies alongside radio-chemotherapy and associated with subjective well-being. The hypothesis that they exert beneficial effects on quality of life and metabolic health in rectal cancer patients is supported by our data. TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT02516501, registered Aug 6th 2015.
PURPOSE: Interest in ketogenic diets (KDs) as complementary nutritional treatments for cancer patients is rising, although some skepticism about their safety exists. We, therefore, studied the effects of KDs on quality of life and blood parameters in rectal cancer patients undergoing radio-chemotherapy. METHODS: EORTC-QLQ30 questionnaire scores and different metabolic and hormonal blood parameters were obtained prior to, in the middle of and at the end of radiotherapy within the KETOCOMP study (ClinicalTrials.gov Identifier: NCT02516501). A total of 18 patients consuming a KD were compared to 23 patients consuming their standard diet (SD). Baseline-end differences were measured using Wilcoxon tests, and repeated measures analysis was performed using linear mixed effects models. RESULTS: Eighty-nine percent of patients on the KD reported subjectively feeling good or very good, but roughly half of them rated the daily routine implementation as difficult. Only the SD group experienced significant declines in physical and role functioning, while the KD group improved in role (p = 0.045), emotional (p = 0.018) and social functioning (p = 0.009).Urinary frequency, buttock pain and fatigue significantly increased in the SD group, but to a much lesser extent in the KD group. Several biomarkers of metabolic health (gamma-glutamyl-transpeptidase, triglyceride-glucose index, HDL cholesterol/triglyceride ratio, and free T3) improved in the KD, but not the SD group. CONCLUSIONS: Despite being perceived as difficult to implement by ≈50% of patients, KDs are feasible as complementary therapies alongside radio-chemotherapy and associated with subjective well-being. The hypothesis that they exert beneficial effects on quality of life and metabolic health in rectal cancer patients is supported by our data. TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT02516501, registered Aug 6th 2015.
Authors: Bryan G Allen; Sudershan K Bhatia; John M Buatti; Kristin E Brandt; Kaleigh E Lindholm; Anna M Button; Luke I Szweda; Brian J Smith; Douglas R Spitz; Melissa A Fath Journal: Clin Cancer Res Date: 2013-06-06 Impact factor: 12.531
Authors: Martin Voss; Marlies Wagner; Nina von Mettenheim; Patrick N Harter; Katharina J Wenger; Kea Franz; Jörg Bojunga; Manuela Vetter; Ruediger Gerlach; Michael Glatzel; Frank Paulsen; Elke Hattingen; Oliver Baehr; Michael W Ronellenfitsch; Emmanouil Fokas; Detlef Imhoff; Joachim P Steinbach; Claus Rödel; Johannes Rieger Journal: Int J Radiat Oncol Biol Phys Date: 2020-06-30 Impact factor: 7.038
Authors: Eugene J Fine; C J Segal-Isaacson; Richard D Feinman; Silvia Herszkopf; Maria C Romano; Norica Tomuta; Amanda F Bontempo; Abdissa Negassa; Joseph A Sparano Journal: Nutrition Date: 2012-07-26 Impact factor: 4.008
Authors: E H Allott; E Macias; S Sanders; B S Knudsen; G V Thomas; S D Hursting; S J Freedland Journal: Prostate Cancer Prostatic Dis Date: 2017-02-28 Impact factor: 5.554
Authors: Benjamin D Hopkins; Chantal Pauli; Xing Du; Diana G Wang; Xiang Li; David Wu; Solomon C Amadiume; Marcus D Goncalves; Cindy Hodakoski; Mark R Lundquist; Rohan Bareja; Yan Ma; Emily M Harris; Andrea Sboner; Himisha Beltran; Mark A Rubin; Siddhartha Mukherjee; Lewis C Cantley Journal: Nature Date: 2018-07-04 Impact factor: 49.962
Authors: Caroline W Cohen; Kevin R Fontaine; Rebecca C Arend; Ronald D Alvarez; Charles A Leath; Warner K Huh; Kerri S Bevis; Kenneth H Kim; John M Straughn; Barbara A Gower Journal: J Nutr Date: 2018-08-01 Impact factor: 4.798
Authors: Mohammed G Abdelwahab; Kathryn E Fenton; Mark C Preul; Jong M Rho; Andrew Lynch; Phillip Stafford; Adrienne C Scheck Journal: PLoS One Date: 2012-05-01 Impact factor: 3.240
Authors: Johannes Rieger; Oliver Bähr; Gabriele D Maurer; Elke Hattingen; Kea Franz; Daniel Brucker; Stefan Walenta; Ulrike Kämmerer; Johannes F Coy; Michael Weller; Joachim P Steinbach Journal: Int J Oncol Date: 2014-04-11 Impact factor: 5.650